CancerDrs

Breast Cancer clinical trials in Arizona

34 actively recruiting breast cancer trials at 8 sites across Arizona.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 2 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll. See the full breast cancer transparency page →

Phase 3 Recruiting Academic/Other

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among prem…

Sponsor: NRG Oncology
NCT ID: NCT05879926
Sites in Arizona:
  • Kingman Regional Medical Center — Kingman, Arizona
  • Cancer Center at Saint Joseph's — Phoenix, Arizona
  • Mayo Clinic Hospital in Arizona — Phoenix, Arizona
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

E-Mindfulness Approaches for Living After Breast Cancer

NRG-CC015 is a prospective, randomized phase III clinical trial to evaluate the efficacy of two distinct digital approaches for delivering a mindfulness-based intervention: a live, instructor-led version delivered over Zoom (MAPs LO), and …

Sponsor: NRG Oncology
NCT ID: NCT06748222
Sites in Arizona:
  • Mayo Clinic Hospital in Arizona — Phoenix, Arizona
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain

This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radia…

Sponsor: NRG Oncology
NCT ID: NCT06500455
Sites in Arizona:
  • Banner University Medical Center - Tucson — Tucson, Arizona
  • University of Arizona Cancer Center-North Campus — Tucson, Arizona
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy

This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard endocrine therapy in patients with ER+/HER2 - early breast cancer with intermediate or high risk for disease recurrence who completed def…

Sponsor: AstraZeneca
NCT ID: NCT05774951
Sites in Arizona:
  • Research Site — Chandler, Arizona
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

This is a randomized, open-label study comparing the efficacy and safety of adjuvant sacituzumab tirumotecan (MK-2870) in combination with pembrolizumab compared to treatment of physician's choice (TPC) in participants with triple-negative…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06393374
Sites in Arizona:
  • Ironwood Cancer & Research Centers-Research ( Site 0054) — Chandler, Arizona
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

The primary objective of the study is to measure efficacy of saruparib (AZD5305) plus camizestrant compared with physician's choice CDK4/6i plus ET in patients with BRCA1, BRCA2, or PALB2m, HR-positive, HER2-negative (defined as IHC 0, 1+,…

Sponsor: AstraZeneca
NCT ID: NCT06380751
Sites in Arizona:
  • Research Site — Gilbert, Arizona
View on ClinicalTrials.gov →
Phase 3 Recruiting Academic/Other

Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial

This phase III trial compares proton craniospinal irradiation (pCSI) to involved-field radiation therapy (IFRT) for the treatment of breast or non-small cell lung cancer that has spread from where it first started to the cerebrospinal flui…

Sponsor: NRG Oncology
NCT ID: NCT06500481
Sites in Arizona:
  • Mayo Clinic Hospital in Arizona — Phoenix, Arizona
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

This is a global, multicenter, open-label, randomized Phase 3 study comparing the efficacy and safety of RLY-2608 (zovegalisib) + fulvestrant to capivasertib + fulvestrant for the treatment of patients with HR+/HER2- ABC with PIK3CA mutati…

Sponsor: Relay Therapeutics, Inc.
NCT ID: NCT06982521
Sites in Arizona:
  • Banner MD Anderson Cancer Center — Gilbert, Arizona
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

The purpose of this study is to compare sacituzumab tirumotecan as a single agent, and in combination with pembrolizumab, versus Treatment of Physician's Choice (TPC) in participants with hormone receptor positive/human epidermal growth fa…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06312176
Sites in Arizona:
  • Ironwood Cancer & Research Centers ( Site 0066) — Chandler, Arizona
  • Banner MD Anderson Cancer Center-Oncology ( Site 0004) — Gilbert, Arizona
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)

Researchers are looking for other ways to treat breast cancer (BC) that is hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) and either unresectable locally advanced or metastatic. * HR positive (H…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT07060807
Sites in Arizona:
  • The University of Arizona Cancer Center - North Campus ( Site 0055) — Tucson, Arizona
View on ClinicalTrials.gov →
Phase 3 Recruiting Network

Conventionally Fractionated vs. Hypofractionated Comprehensive Nodal Irradiation for Breast Cancer Using Pencil Beam Scanning Proton Therapy

The purpose of this research study is to learn more about the effects of using proton radiation therapy delivered over a shorter course of treatment (3 weeks) compared with a longer, standard course of treatment (5 weeks) for women with br…

Sponsor: Proton Collaborative Group
NCT ID: NCT05856773
Sites in Arizona:
  • Mayo Clinic — Scottsdale, Arizona
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

The purpose of this study is to further advance the ability to practice personalized medicine by learning which new drug agents are most effective with which types of breast cancer tumors and by learning more about which early indicators o…

Sponsor: QuantumLeap Healthcare Collaborative
NCT ID: NCT01042379
Sites in Arizona:
  • Mayo Clinic - Scottsdale — Scottsdale, Arizona
  • University of Arizona — Tucson, Arizona
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

Efficacy and Safety Study of Halneuron in the Treatment of Chemotherapy-Induced Neuropathic Pain

A randomized study to determine safety and efficacy of a series of subcutaneous (SC) injections of HAL in patients with CINP, compared to matching placebo injections. After that, subjects may have the option to enter an Open Label extensio…

Sponsor: Dogwood Therapeutics Inc.
NCT ID: NCT06848348
Sites in Arizona:
  • Central Recruiting Site — Glendale, Arizona
  • Central Recruiting Site — Phoenix, Arizona
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer

The Substudy Protocol ASPEN-09-03 is a Phase 2, single-arm, multicenter study evaluating the efficacy, safety, and tolerability of evorpacept in combination with trastuzumab and chemotherapy in participants with HER2-positive metastatic br…

Sponsor: ALX Oncology Inc.
NCT ID: NCT07007559
Sites in Arizona:
  • The University of Arizona Cancer Center - North Campus — Tucson, Arizona
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer

This is an open label, multicenter, single arm phase II study to evaluate the efficacy and safety of ribociclib and ET in patients with locoregional recurrence of HR-positive, HER2-negative breast cancer.

Sponsor: Oana Danciu
NCT ID: NCT05467891
Sites in Arizona:
  • University of Arizona — Phoenix, Arizona
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer

This is an adaptive Phase 2, open-label, randomized, multi-center study evaluating up to 2 regimens of PCS6422 with capecitabine (Cap) vs. standard dose of Cap alone in patients with advanced or metastatic breast cancer. The goal of the st…

Sponsor: Processa Pharmaceuticals
NCT ID: NCT06568692
Sites in Arizona:
  • Arizona Oncology Associates — Tucson, Arizona
View on ClinicalTrials.gov →
Phase 2 Recruiting Network

Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer

The purpose of this research study is to compare the effects (good and bad) on women and their cancer using proton radiation therapy. This study is being done to see if proton radiation therapy will prove to be beneficial for women with ea…

Sponsor: Proton Collaborative Group
NCT ID: NCT01766297
Sites in Arizona:
  • Mayo Clinic — Scottsdale, Arizona
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067

This is a multiphase, multicenter study, which includes a Phase 1a open-label, dose escalation monotherapy study of ST-067 given as an SC injection with or without obinutuzumab \[Gazyva®\] pre-treatment, by IV infusion, and in combination …

Sponsor: Simcha IL-18, Inc.
NCT ID: NCT04787042
Sites in Arizona:
  • HonorHealth Research Institute — Scottsdale, Arizona
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and therapeutic activity of GI-102 as a single agent and in combination with conventional anti-cancer drugs, pembrolizumab or trastuzumab deruxtecan(T-DXd…

Sponsor: GI Innovation, Inc.
NCT ID: NCT05824975
Sites in Arizona:
  • Mayo Clinic in Arizona — Scottsdale, Arizona
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

Phase 1 dose escalation and expansion study of CLSP-1025, a first-in-class HLA-A\*02:01 specific T cell engager (TCE) targeting solid tumors that harbor the p53 R175H mutation.

Sponsor: Clasp Therapeutics, Inc.
NCT ID: NCT06778863
Sites in Arizona:
  • HonorHealth Research Institute — Scottsdale, Arizona
  • The University of Arizona Cancer Center — Tucson, Arizona
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors

This is an open-label, phase 1/1b study evaluating the safety, tolerability, pharmacokinetic (what the body does to the drug), pharmacodynamic (what the drug does to the body), and antitumor activity of CGT4255 in adult participants with a…

Sponsor: Cogent Biosciences, Inc.
NCT ID: NCT07361562
Sites in Arizona:
  • HonorHealth Research Institute — Scottsdale, Arizona
  • Mayo Scottsdale — Scottsdale, Arizona
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer

This is a Phase 1b open-label, 2-part study in 3 treatment groups. The 3 treatment groups are as follows: Treatment Group 1: Palazestrant (OP-1250) in combination with ribociclib (KISQALI®, Novartis Pharmaceuticals Corporation). Treatment …

Sponsor: Olema Pharmaceuticals, Inc.
NCT ID: NCT05508906
Sites in Arizona:
  • Banner MD Anderson Cancer Center — Gilbert, Arizona
View on ClinicalTrials.gov →

Showing 25 of 34 trials with sites in Arizona. See all breast cancer trials →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-09-07